Share on StockTwits

Avalanche Biotechnologies (NASDAQ: AAVL) was the recipient of a ratings changes during the seven days:

  • Avalanche Biotechnologies is now covered by analysts at Piper Jaffray. They set an “overweight” rating and a $39.00 price target on the stock.
  • Avalanche Biotechnologies is now covered by analysts at Jefferies Group. They set a “buy” rating and a $40.00 price target on the stock.
  • Avalanche Biotechnologies is now covered by analysts at William Blair. They set an “outperform” rating and a $52.00 price target on the stock.
  • Avalanche Biotechnologies is now covered by analysts at Cowen and Company. They set an “outperform” rating and a $45.00 price target on the stock.

Shares of Avalanche Biotechnologies Inc (NASDAQ:AAVL) opened at 30.25 on Tuesday. Avalanche Biotechnologies Inc has a 52-week low of $22.00 and a 52-week high of $32.375. The stock’s 50-day moving average is $26.50 and its 200-day moving average is $26.50. The company’s market cap is $646.1 million.

Avalanche Biotechnologies, Inc (NASDAQ:AAVL) is a biotechnology company focused on discovering and developing novel gene therapies to transform the lives of patients with sight-threatening ophthalmic diseases.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.